Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitorsRami Rahal, Christoph Lengauer, Paul Fleming et al.|Cancer Research|2016Cited by 17
Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancersYoon Jong Choi, Marion Dorsch, Steve Wenglowsky et al.|Cancer Research|2021Cited by 7